NCT01266005View on ClinicalTrials.gov

A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients

PHASE4TerminatedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

January 31, 2014

Conditions
Chronic Hepatitis B
Interventions
DRUG

Clevudine

30mg,QD

DRUG

Entecavir

0.5mg QD

Trial Locations (1)

Unknown

9 Sites, Seoul

Sponsors
All Listed Sponsors
lead

Bukwang Pharmaceutical

INDUSTRY

NCT01266005 - A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients | Biotech Hunter | Biotech Hunter